Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Gastroenterology
    • Repeated ketamine...

    Repeated ketamine infusions do not cause hepatotoxicity reveals study

    Written by Medha Baranwal Baranwal Published On 2019-11-08T19:25:45+05:30  |  Updated On 15 Dec 2023 12:07 PM IST
    Repeated ketamine infusions do not cause hepatotoxicity reveals study

    USA: The repeated infusions of ketamine treatment for pain and migraine does not increase a patient's risk for hepatotoxicity and adverse drug events, reveal results of a recent study presented at the 18th Annual Pain Medicine Meeting.


    Ketamine is a common and effective treatment for acute and chronic pain conditions. Some previous research has shown it to be associated with hepatotoxicity and ADEs.


    Andrew Mendelson, Thomas Jefferson University Hospital in Philadelphia, PA, and colleagues evaluated the impact of ketamine by designing a multicenter cohort study using patients admitted to Thomas Jefferson University Hospital and UVA Pain Management Center from 2014 through 2018.


    For the study, the researchers retrospectively reviewed the records of 114 patients who had undergone either a single admission or multiple admissions for treatment of refractory headache or pain for five-day ketamine infusions, used off-label, at two institutions and compared the incidence of elevated liver function tests (LFTs) and psychomimetic ADEs between initial and repeated ketamine treatments.


    Overall, the mean age of the study population was 46 years and 85 of the participants were female. Minimum time spent between ketamine infusion during the study was 8 weeks and the mean time between first and second infusions was 152 days.


    Also Read: Pain management with ketamine infusion: Most patients may experience side effects, study suggests


    Key findings include:

    • The mean maximum ketamine rate during admission was 0.70 mg/kg/h and elevated liver function tests at baseline were reported in 30.7% of total admissions.

    • No statistically significant association were noted between elevated liver function tests and admission status (initial vs. repeat).

    • No association were observed between the presence of hallucinations and vivid dreams and admission status.

    • The patients who underwent repeated infusion had a lower incidence of nausea and vomiting than those undergoing a single admission.

    • Patients who underwent repeated infusion also reported less sedation than patients with single admissions.


    Also Read: Ketamine and dexmedetomidine combo requires close watch in surgical patients

    “Given the overall high incidence of elevated liver function tests in this population, we recommend baseline and at least one additional set of liver function tests at the end of treatment to monitor for toxicity as well as follow-up for any patient with elevated liver function tests at the end of treatment,” investigators wrote.


    This study, “A Multicenter Retrospective Study of Adverse Effects from Ketamine for Refractory Headache and CRPS,” will be presented on November 15, 2019, during the 18th Annual Pain Medicine Meeting in New Orleans, LA.

    18th Annual Pain Medicine Meetingacute painadverse drug eventsAndrew Mendelsonchronic painhepatotoxicityKetamineMedical newsmigrainePainrecent medical newsrepeated ketamine infusionstoxicity
    Source : 18th Annual Pain Medicine Meeting

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok